Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
- 19 December 2017
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (4), 1104-1106
- https://doi.org/10.1093/jac/dkx496
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2017
- In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015Antimicrobial Agents and Chemotherapy, 2017
- Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae BacteremiaAntimicrobial Agents and Chemotherapy, 2017
- Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?Antimicrobial Agents and Chemotherapy, 2017
- Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant OrganismsAntimicrobial Agents and Chemotherapy, 2017
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.Clinical Infectious Diseases, 2016
- Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015Eurosurveillance, 2015
- Global Spread of Carbapenemase-producingEnterobacteriaceaeEmerging Infectious Diseases, 2011